Nature Reviews Cancer 10, 9–22 (2010)
On page 17 of this article, in the section Targeting αvβ3 and αvβ5 the sentence at the start of the second paragraph that reads “Cilengitide is an inhibitor of both αvβ3 and αvβ5 integrins, and it was selected in our laboratory by screening a library of cyclic RGD peptides in a cell-free receptor assay for their capacity to inhibit integrins αvβ3 and αvβ5 but not αΙΙbβ3 REF. 130).” was incorrectly phrased. The corrected sentence with additional references is given below.
“Cilengitide is an inhibitor of both αvβ3 and αvβ5 integrins. We had shown that αvβ3 and αvβ5 integrins were important regulators of angiogenesis and tumour growth49,51,191,192 and developed a cell-free receptor assay to select for antagonists of integrins αvβ3 and αvβ5 that did not effect integrin αΙΙbβ3 REF. 130). This assay was used to screen a library of integrin binding cyclic RGD peptides designed and synthesized by H. Kessler and colleagues for αvβ3 activity and selectivity193,194,195 from which cilengitide was developed196”.
References
Cheresh, D. A. Human endothelial cells synthesize and express an Arg Gly Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc. Natl. Acad. Sci. USA 84, 6471–6475 (1987).
Brooks, P. C. et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79, 1157–1164 (1994).
Aumailley, M. et al. Arg Gly Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett. 291, 50–54 (1991).
Gurrath, M. et al., Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides; Eur. J. Biochem., 210, 911–921 (1992).
Pfaff, M. et al., Selective Recognition of Cyclic RGD Peptides of NMR Defined Conformation by αIIbβ3, αVβ3 and α5β1 Integrins. J. Biol. Chem., 269, 20233–20238 (1994).
Dechantsreiter, M. A. et al. N-Methylated cyclic RGD peptides as highly active and selective αVβ3 integrin antagonists. J. Med. Chem. 42, 3033–3040 (1999).
Additional information
The online version of the original article can be found at 10.1038/nrc2748
Rights and permissions
About this article
Cite this article
Desgrosellier, J., Cheresh, D. Erratum: Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10, 890 (2010). https://doi.org/10.1038/nrc2965
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc2965
This article is cited by
-
LncRNA NEAT1 Enhances Glioma Progression via Regulating the miR-128-3p/ITGA5 Axis
Molecular Neurobiology (2021)
